

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Ltd
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Vincent Ippolito
<b>Date of last notice</b>	17 April 2026

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change</b>	<b>Vincent Peter Ippolito</b> 16,000,000 Performance Rights (expiring 2 December 2029)  <b>Vincent Peter Ippolito and Karen Ann Ippolito &lt;The Ippolito Trust&gt; - trustee and beneficiary of the trust</b> 16,668,311 Fully Paid Ordinary Shares
<b>Class</b>	Unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Number acquired</b>	1,666,667
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – Corresponding offer of options alongside participation in Share placement

<b>No. of securities held after the change</b>	<b>Vincent Peter Ippolito</b> 16,000,000 Performance Rights (expiring 2 December 2029)  <b>Vincent Peter Ippolito and Karen Ann Ippolito &lt;The Ippolito Trust&gt; - trustee and beneficiary of the trust</b> 16,668,311 Fully Paid Ordinary Shares  1,666,667 unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Corresponding grant of options alongside Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	Yes
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
<b>If prior written clearance was provided, on what date was this provided?</b>	7 March 2026

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Botanix Pharmaceuticals Ltd
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Henry William Bosch
<b>Date of last notice</b>	17 April 2026

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change</b>	20,503,369 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029)
<b>Class</b>	Unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Number acquired</b>	1,666,667
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – Corresponding offer of options alongside participation in Share placement
<b>No. of securities held after change</b>	20,503,369 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029) 1,666,667 unquoted options exercisable at \$0.06, expiring on 31 January 2027

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Corresponding grant of options alongside Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.
---	--

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Yes
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
<b>If prior written clearance was provided, on what date was this provided?</b>	7 March 2026

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Botanix Pharmaceuticals Ltd
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Daniel Sharp
<b>Date of last notice</b>	17 April 2026

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd <Daniel H Sharp TT A/C> Mr Sharp is a beneficiary
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change</b>	<b>DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd</b> 2,131,313 Fully Paid Ordinary Shares 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 333,333 Performance Rights (expiring 30 November 2026) 3,000,000 Performance Rights (expiring 2 December 2029) <b>&lt;Daniel H Sharp TT A/C&gt; Mr Sharp is a beneficiary</b> 833,333 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

For personal use only

<b>Class</b>	Unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Number acquired</b>	833,333
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – Corresponding offer of options alongside participation in Share placement
<b>No. of securities held after change</b>	<p><b>DJMB Corporate Pty Ltd</b> - Mr Sharp is a director of DJMB Corporate Pty Ltd</p> <p>2,131,313 Fully Paid Ordinary Shares</p> <p>4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025</p> <p>333,333 Performance Rights (expiring 30 November 2026)</p> <p>3,000,000 Performance Rights (expiring 2 December 2029)</p> <p><b>&lt;Daniel H Sharp TT A/C&gt; Mr Sharp is a beneficiary</b></p> <p>833,333 Fully Paid Ordinary Shares</p> <p>833,333 unquoted options exercisable at \$0.06, expiring on 31 January 2027</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Corresponding grant of options alongside Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 Closed Period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Botanix Pharmaceuticals Ltd
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Patricia Walker
<b>Date of last notice</b>	17 April 2026

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (Including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change</b>	1,666,667 Fully Paid Ordinary Shares 1,000,000 unquoted options exercisable at \$0.145, expiring on 22 August 2026 4,000,000 unquoted options exercisable at \$0.19, expiring on 22 August 2028 4,000,000 unquoted options exercisable at \$0.28, expiring on 12 July 2027
<b>Class</b>	Unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Number acquired</b>	1,666,667
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

For personal use only

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil – Corresponding offer of options alongside participation in Share placement
<b>No. of securities held after change</b>	1,666,667 Fully Paid Ordinary Shares  1,000,000 unquoted options exercisable at \$0.145, expiring on 22 August 2026  4,000,000 unquoted options exercisable at \$0.19, expiring on 22 August 2028  4,000,000 unquoted options exercisable at \$0.28, expiring on 12 July 2027  1,666,667 unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Corresponding grant of options alongside Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 Closed Period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Botanix Pharmaceuticals Ltd
<b>ABN</b>	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Stewart Washer
<b>Date of last notice</b>	17 April 2026

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (Including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr Stewart James Washer + Dr Patrizia Derna Washer "<Washer Family S/Fund a/c>", - Dr Washer is a trustee and beneficiary of the trust.
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change</b>	<p><b>Dr Stewart James Washer + Dr Patrizia Derna Washer &lt;The Washer Family A/C&gt; - Dr Washer is a trustee and beneficiary of the trust.</b></p> <ul style="list-style-type: none"> <li>• 654,884 Fully Paid Ordinary Shares</li> <li>• 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025</li> <li>• 333,333 Performance Rights (expiring 30 November 2026) *</li> <li>• 3,000,000 Performance Rights (expiring 2 December 2029)</li> </ul> <p><b>Mal Washer Nominees Pty Ltd - Dr Washer is a Director.</b></p> <ul style="list-style-type: none"> <li>• 1,515,151 Fully Paid Ordinary Shares</li> </ul>

+ See chapter 19 for defined terms.

For personal use only

	<p><b>Dr Stewart James Washer + Dr Patrizia Derna Washer &lt;The Washer Family A/C&gt;</b> - Dr Washer is a trustee and beneficiary of the trust.</p> <ul style="list-style-type: none"> <li>• 1,666,667 Fully Paid Ordinary Shares</li> </ul>
<b>Class</b>	Unquoted options exercisable at \$0.06, expiring on 31 January 2027
<b>Number acquired</b>	1,666,667
<b>Number disposed</b>	Nil
<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation</p>	Nil – Corresponding offer of options alongside participation in Share placement
<b>No. of securities held after change</b>	<p><b>Dr Stewart James Washer + Dr Patrizia Derna Washer &lt;The Washer Family A/C&gt;</b> - Dr Washer is a trustee and beneficiary of the trust.</p> <ul style="list-style-type: none"> <li>• 654,884 Fully Paid Ordinary Shares</li> <li>• 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025</li> <li>• 333,333 Performance Rights (expiring 30 November 2026) *</li> <li>• 3,000,000 Performance Rights (expiring 2 December 2029)</li> </ul> <p><b>Mal Washer Nominees Pty Ltd</b> - Dr Washer is a Director.</p> <ul style="list-style-type: none"> <li>• 1,515,151 Fully Paid Ordinary Shares</li> </ul> <p><b>Dr Stewart James Washer + Dr Patrizia Derna Washer &lt;The Washer Family A/C&gt;</b> - Dr Washer is a trustee and beneficiary of the trust.</p> <p>1,666,667 Fully Paid Ordinary Shares</p> <p>1,666,667 unquoted options exercisable at \$0.06, expiring on 31 January 2027</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Corresponding grant of options alongside Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 Closed Period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

+ See chapter 19 for defined terms.

For personal use only